You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
McKinsey
Dow
Baxter
Boehringer Ingelheim

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Patent: 6,803,197

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,803,197
Title: Method for determining susceptibility to bone damage by screening polymorphisms in the vitamin D receptor gene
Abstract:The present invention relates to a prognostic method and means for determining susceptibility to bone damage in a subject, by screening for polymorphisms in the Vitamin D receptor or collagen I.alpha.1 genes. In particular, the method for determining susceptibility to bone damage comprises analyzing the genetic material of a subject to determine which of the B/b, A/a or T/t alleles of the restriction enzyme sites BsmI, ApaI and TaqI respectively are present. The method may further comprise determining which allele is present at die SpI restriction site of the collagen I.alpha.1 gene. Specific combinations of the above alleles represent a haplotype which is associated with susceptibility to bone damage.
Inventor(s): Uitterlinden; Andreas Gerardus (Poortugaal, NL), Van Leeuwen; Johannes Petrus Thomas Maria (Amstelveen, NL), Pols; Huibert Adriaan Pieter (Papendrecht, NL)
Assignee: Erasmus Universiteit Rotterdam (Rotterdam, NL)
Application Number:09/786,991
Patent Claims:see list of patent claims

Details for Patent 6,803,197

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Emergent Biosolutions Canada Inc. BAT botulism antitoxin heptavalent LIQUID 125462 1 2013-03-01   Start Trial Erasmus Universiteit Rotterdam (Rotterdam, NL) 2018-09-10 search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Erasmus Universiteit Rotterdam (Rotterdam, NL) 2018-09-10 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Erasmus Universiteit Rotterdam (Rotterdam, NL) 2018-09-10 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Erasmus Universiteit Rotterdam (Rotterdam, NL) 2018-09-10 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Dow
Colorcon
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.